Literature DB >> 589316

Defective blood glucose counter-regulation in diabetics is a selective form of autonomic neuropathy.

L V Campbell, E W Kraegen, L Lazarus.   

Abstract

Administration of a low-dose insulin infusion to normal subjects results in a mild drop in blood glucose concentration (1.1 mmol/1 (20 mg/100 ml)) and the resetting of the basal glucose at the lower concentration. Clinical hypoglycaemia does not develop, and there is a significant release of glucagon, growth hormone, and cortisol. A similar infusion in insulin-requiring diabetics results in hypoglycaemia accompanied by a release of growth hormone and cortisol but no significant release of glucagon. Subsequently giving arginine to these patients results in a significant release of glucagon, indicating that the alpha cell is intact and can respond to local, direct stimulation. In one patient the defect in glucagon response to impending hypoglycaemia developed after two years' insulin treatment. This type of dissociated response' of the alpha cell has been reported in animals after denervation of the pancreas, and insulin-requiring diabetics may develop a selective form of autonomic neuropathy affecting the vagal control of glucagon release.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 589316      PMCID: PMC1632815          DOI: 10.1136/bmj.2.6101.1527

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  14 in total

1.  The beta cell and its responses: summarizing remarks and some contributions from Geneva.

Authors:  A E Renold
Journal:  Diabetes       Date:  1972       Impact factor: 9.461

2.  The effect of truncal and selective vagotomy on the release of pancreatic glucagon, insulin and enteroglucagon.

Authors:  R C Russell; J P Thomson; S R Bloom
Journal:  Br J Surg       Date:  1974-10       Impact factor: 6.939

3.  The role of the autonomic nervous system in the control of glucagon release during insulin hypoglycaemia in the calf.

Authors:  N J Vaughan; S R Bloom; O Ogawa; P M Bircham; A V Edwards
Journal:  Experientia       Date:  1973

4.  Nature of islet-cell innervation in the cat pancreas.

Authors:  A C Esterhuizen; T L Spriggs; J D Lever
Journal:  Diabetes       Date:  1968-01       Impact factor: 9.461

5.  Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect.

Authors:  J E Gerich; M Langlois; C Noacco; J H Karam; P H Forsham
Journal:  Science       Date:  1973-10-12       Impact factor: 47.728

6.  Lack of glucagon response to hypoglycemia in diabetic autonomic neuropathy.

Authors:  T D Maher; R J Tanenberg; B Z Greenberg; J E Hoffman; R P Doe; F C Goetz
Journal:  Diabetes       Date:  1977-03       Impact factor: 9.461

7.  Glucagon secretion from the perfused rat pancreas. Studies with glucose and catecholamines.

Authors:  G C Weir; S D Knowlton; D B Martin
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

8.  The effect of adrenergic blockade on the glucagon responses to starvation and hypoglycemia in man.

Authors:  R M Walter; R J Dudl; J P Palmer; J W Ensinck
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

9.  Vagal control of glucagon release in man.

Authors:  S R Bloom; N J Vaughan; R C Russell
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

10.  A long-term diabetic autonomic nervous abnormality. Reduced variations in resting heart rate measured by a simple and sensitive method.

Authors:  H J Gundersen; B Neubauer
Journal:  Diabetologia       Date:  1977-04       Impact factor: 10.122

View more
  14 in total

1.  Can beta-blockers be used in diabetic patients?

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

2.  Hormonal responses to insulin infusion in diabetes mellitus.

Authors:  L V Campbell; E W Kraegen; H Meler; L Lazarus
Journal:  Diabetologia       Date:  1979-06       Impact factor: 10.122

3.  Unawareness of hypoglycaemia and inadequate hypoglycaemic counterregulation: no causal relation with diabetic autonomic neuropathy.

Authors:  R E Ryder; D R Owens; T M Hayes; M A Ghatei; S R Bloom
Journal:  BMJ       Date:  1990-10-06

4.  Role of glucose and insulin in the dynamic regulation of glucagon release by the perfused rat pancreas.

Authors:  V Leclercq-Meyer; J Marchand; W J Malaisse
Journal:  Diabetologia       Date:  1983-03       Impact factor: 10.122

Review 5.  Status of pancreatic transplants and mechanical devices for blood glucose control in diabetes.

Authors:  J V Santiago; N H White
Journal:  Ann Biomed Eng       Date:  1980       Impact factor: 3.934

6.  Counterregulation in type 2 (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis.

Authors:  S R Heller; I A Macdonald; R B Tattersall
Journal:  Diabetologia       Date:  1987-12       Impact factor: 10.122

7.  Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus.

Authors:  D A Popp; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

8.  Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions.

Authors:  G B Bolli; E Tsalikian; M W Haymond; P E Cryer; J E Gerich
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

9.  Improved but not normalized glucose counter-regulation during glucagon infusion in Type 1 (insulin-dependent) diabetes.

Authors:  I Lager; H von Schenck; U Smith
Journal:  Diabetologia       Date:  1984-05       Impact factor: 10.122

10.  Autonomic dysfunction and severe hypoglycaemia in insulin dependent diabetes mellitus.

Authors:  L Barkai; L Madácsy; I Vámosi
Journal:  Arch Dis Child       Date:  1991-12       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.